What is Morphogenesis?
Morphogenesis, operating within the biopharmaceutical sector, is dedicated to the advancement of innovative immune therapies. The company's pipeline includes IMMUNE FX (IFX), an innate immune agonist, and bi-specific immune modulating antibody drug conjugates (ADCs) such as TBS-2025. A key focus is the IFX-2.0 Phase 3 registration trial, underscoring the company's commitment to bringing novel treatments to market. Morphogenesis aims to serve clients seeking cutting-edge solutions for immune-related conditions, positioning itself as a contributor to the field of immunotherapy through rigorous scientific research and development.
How much funding has Morphogenesis raised?
Morphogenesis has raised a total of $22.1M across 5 funding rounds:
Private Equity
$2.7M
Series A
$16M
Debt
$350K
Other Financing Round
$2.7M
Debt
$294K
Private Equity (2017): $2.7M, investors not publicly disclosed
Series A (2018): $16M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Other Financing Round (2020): $2.7M, investors not publicly disclosed
Debt (2021): $294K backed by PPP
What's next for Morphogenesis?
The substantial enterprise-level funding and recent strategic investment indicate that Morphogenesis is poised for significant scaling and pipeline acceleration. This capital infusion is expected to fuel further clinical development, potentially expanding the reach of its IMMUNE FX (IFX) and TBS-2025 programs. The company's strategic focus on immunotherapy suggests a trajectory aimed at addressing unmet needs in immune-related diseases, with future endeavors likely involving further research, strategic partnerships, and market penetration within the biopharmaceutical industry.
See full Morphogenesis company page
